Genetic analysis of polymorphisms in dopamine receptor and transporter genes for association with smoking among cancer patients

European Addiction Research

Volumn 19, Issue 2, 2013, Pages 105-111

  Gordiev, Marat ^a   Engstrom, Paul F ^b   Khasanov, Rustem ^a   Moroshek, Anton ^a   Sitdikov, Rustem ^a   Dgavoronkov, Vladamir ^a   Schnoll, Robert A ^c  

^a Tatarstan Regional Clinical Cancer Center   (Russian Federation)

^b FOX CHASE CANCER CENTER   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Cancer patients; DRD2; DRD4; Gene; Russia; SLC6A3; Tobacco

Indexed keywords

DOPAMINE; DOPAMINE 2 RECEPTOR; DOPAMINE 4 RECEPTOR; DOPAMINE TRANSPORTER;

ADULT; ALLELE; ARTICLE; CANCER PATIENT; FEMALE; GENE FREQUENCY; GENE INTERACTION; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MOLECULAR WEIGHT; PRIORITY JOURNAL; SMOKING; SMOKING CESSATION; TANDEM REPEAT; TOBACCO DEPENDENCE; TOBACCO USE;

EID: 84868231954     PISSN: 10226877     EISSN: 14219891     Source Type: Journal    
DOI: 10.1159/000341711     Document Type: Article

References (42)

1. Schnoll RA, Engstrom PF, Subramanian S, Demidov L, Wielt D, Tighiouart M: Prevalence and correlates of tobacco use among Russian cancer patients: implications for the development of smoking cessation interventions at a cancer center in Russia. Int J Behav Med 2006; 13: 16-25.
2. Schnoll RA, Subramanian S, Engstrom PF, Martinez E: Correlates of continued tobacco use and intention to quit smoking among Russian cancer patients. Int J Behav Med 2011; 18: 325-332.
3. Klosky JL, Tyc VL, Garces-Webb DM, Buscemi J, Klesges RC, Hudson MM: Emerging issues in smoking among adolescent and adult cancer survivors: a comprehensive review. Cancer 2007; 110: 2408-2419.
4. Markou A: Neurobiology of nicotine dependence. Philos Trans R Soc Lond B Biol Sci 2008; 363: 3159-3168.
5. Mifsud JC, Hernandez, L, Hoebel, BG: Nicotine infused into the nucleus accumbens increases synaptic dopamine as measured by in vivo microdialysis. Brain Res 1989; 478: 365-367.
6. Pidoplichko VI, DeBiasi M, Williams JT, Dani JA: Nicotine activates and desensitizes midbrain dopamine neurons. Nature 1997; 390: 401-404.
7. Rice ME, Cragg SJ: Nicotine amplifies reward-related dopamine signals in striatum. Nat Neurosci 2004; 7: 583-584.
8. Rao TS, Correa, LD, Adams, P, Santori, EM, Sacaan, AI: Pharmacological characterization of dopamine, norepinephrine and serotonin release in the rat prefrontal cortex by neuronal nicotinic acetylcholine receptor agonists. Brain Res 2003; 990: 203-208.
9. Nestler EJ: Is there a common molecular pathway for addiction? Nat Neurosci 2005; 8: 1445-1449.
10. Ray R, Schnoll RA, Lerman C: Nicotine dependence and pharmacogenetics; in Steptoe A (ed): Handbook of Behavioral Medicine. New York, Springer, 2010, pp 479-498.
11. Schnoll RA, Leone F: Biomarkers to optimize the treatment of nicotine dependence. Biomark Med 2011; 5: 745-761.
12. Thompson J, Thomas N, Singleton A, Piggott M, Lloyd S, Perry EK, Morris CM, Perry RH, Ferrier IN, Court JA: D2 dopamine receptor gene (DRD2) Taq1 A polymorphism: reduced dopamine D2 receptor binding in the human striatum associated with the A1 allele. Pharmacogenetics 1997; 7: 479-484.
13. Comings DE, Ferry L, Bradshaw-Robinson S, Burchette R, Chiu C, Muhleman D: The dopamine D2 receptor (DRD2) gene: a genetic risk factor in smoking. Pharmacogenetics 1996; 6: 73-79.
14. Laucht M, Becker K, Frank J, Schmidt MH, Esser G, Treutlein J, Skowronek MH, Schumann G: Genetic variation in dopamine pathways differentially associated with smoking progression in adolescence. J Am Acad Child Adolesc Psychiatry 2008; 47: 673-681.
15. Audrain-McGovern J, Lerman C, Wileyto EP, Rodriguez D, Shields PG: Interacting effects of genetic predisposition and depression on adolescent smoking progression. Am J Psychiatry 2004; 161: 1224-1230.
16. Munafò M, Johnstone EC, Murphy MF, Aveyard P: Lack of association of DRD2 rs1800497 (Taq1A) polymorphism with smoking cessation in a nicotine replacement therapy randomized trial. Nicotine Tob Res 2009; 11: 404-407.
17. Heinz A, Goldman D, Jones DW, Palmour R, Hommer D, Gorey JG, Lee KS, Linnoila M, Weinberger DR: Genotype influences in vivo dopamine transporter availability in human striatum. Neuropsychopharmacology 2000; 22: 133-139.
18. Lerman C, Caporaso NE, Audrain J, Main D, Bowman ED, Lockshin B, Boyd NR, Shields PG: Evidence suggesting the role of specific genetic factors in cigarette smoking. Health Psychol 1999; 18: 14-20.
19. Sabol SZ, Nelson ML, Fisher C, Gunzerath L, Brody CL, Hu S, Sirota LA, Marcus SE, Greenberg BD, Lucas FR 4th, Benjamin J, Murphy DL, Hamer DH: A genetic association for cigarette smoking behavior. Health Psychol 1999; 18: 7-13.
20. Timberlake DS, Haberstick BC, Lessem JM, Smolen A, Ehringer M, Hewitt JK, Hopfer C: An association between the DAT1 polymorphism and smoking behavior in young adults from the National Longitudinal Study of Adolescent Health. Health Psychol 2006; 25: 190-197.
21. Jorm AF, Henderson AS, Jacomb PA, Christensen H, Korten AE, Rodgers B, Tan X, Easteal S: Association of smoking and personality with a polymorphism of the dopamine transporter gene: results from a community survey. Am J Med Genet 2000; 12: 331-334.
22. Asghari V, Sanyal S, Buchwaldt S, Paterson A, Jovanovic V, Van Tol HH: Modulation of intracellular cyclic AMP levels by different human dopamine D4 receptor variants. J Neurochem 1995; 65: 1157-1165.
23. David SP, Munafò MR, Murphy MF, Proctor M, Walton RT, Johnstone EC: Genetic variation in the dopamine D4 receptor (DRD4) gene and smoking cessation: follow-up of a randomised clinical trial of transdermal nicotine patch. Pharmacogenomics J 2008; 8: 122-128.
24. Shields PG, Lerman C, Audrain J, Bowman ED, Main D, Boyd NR, Caporaso NE: Dopamine D4 receptors and the risk of cigarette smoking in African-Americans and Caucasians. Cancer Epidemiol Biomarkers Prev 1998; 7: 453-458.
25. David SP, Munafò MR: Genetic variation in the dopamine pathway and smoking cessation. Pharmacogenomics 2008; 9: 1307-1321.
26. Das D, Tan X, Easteal S: Effect of model choice in genetic association studies: DRD4 exon III VNTR and cigarette use in young adults. Am J Med Genet B Neuropsychiatr Genet 2011; 156B:346-351.
27. Singleton AB, Thomson JH, Morris CM, Court JA, Lloyd S, Cholerton S: Lack of association between the dopamine D2 receptor gene allele DRD2 ∗ A1 and cigarette smoking in a United Kingdom population. Pharmacogenetics 1998; 8: 125-128.
28. Wacholder S, Rothman N, Caporaso N: Population stratification in epidemiologic studies of common genetic variants and cancer: quantification of bias. J Natl Cancer Inst 2000; 92: 1151-1158.
29. USDHHS: Smoking: Facts and Tips for Quitting. Bethesda, National Institutes of Health, 1993.
30. Radloff LS: The CES-D: a self-report depression scale for research in the general population. Appl Psychol Meas 1977; 1: 385-401.
31. Vandenbergh DJ, Persico AM, Hawkins AL, Griffin CA, Li X, Jabs EW, Uhl GR: Human dopamine transporter gene (DAT1) maps to chromosome 5p15.3 and displays a VNTR. Genomics 1992; 14: 1104-1106.
32. Prokhorov AV, Hudmon KS, Gritz ER: Promoting smoking cessation among cancer patients: a behavioral model. Oncology 1997; 1807-1813.
33. Heatherton TF, Kozlowski LT, Frecker RC, Fagerström KO: The Fagerström test for nicotine dependence: a revision of the Fagerström tolerance questionnaire. Br J Addict 1991; 86: 1119-1127.
34. Sieminska A, Buczkowski K, Jassem E, Niedoszytko M, Tkacz E: Influences of polymorphic variants of DRD2 and SLC6A3 genes, and their combinations on smoking in Polish population. BMC Med Genet 2009; 10: 92.
35. Noble EP, St Jeor ST, Ritchie T, Syndulko K, St Jeor SC, Fitch RJ, Brunner RL, Sparkes RS: D2 dopamine receptor gene and cigarette smoking: a reward gene? Med Hypotheses 1994; 42: 257-260.
36. Hamajima N, Ito H, Matsuo K, Saito T, Tajima K, Ando M, Yoshida K, Takahashi T: Association between smoking habits and dopamine receptor D2 taqI A A2 allele in Japanese males: a confirmatory study. J Epidemiol 2002; 12: 297-304.
37. Yoshida K, Hamajima N, Kozaki Ki, Saito H, Maeno K, Sugiura T, Ookuma K, Takahashi T: Association between the dopamine D2 receptor A2/A2 genotype and smoking behavior in the Japanese. Cancer Epidemiol Biomarkers Prev 2001; 10: 403-405.
38. Munafò MR, Timpson NJ, David SP, Ebrahim S, Lawlor DA: Association of the DRD2 gene Taq1A polymorphism and smoking behavior: a meta-analysis and new data. Nicotine Tob Res 2009; 11: 64-76.
39. McGuire V, Van Den Eeden SK, Tanner CM, Kamel F, Umbach DM, Marder K, Mayeux R, Ritz B, Ross GW, Petrovitch H, Topol B, Popat RA, Costello S, Manthripragada AD, Southwick A, Myers RM, Nelson LM: Association of DRD2 and DRD3 polymorphisms with Parkinson's disease in a multiethnic consortium. J Neurol Sci 2011; 307: 22-29.
40. Lerman C, Caporaso N, Main D, Audrain J, Boyd NR, Bowman ED, Shields PG: Depression and self-medication with nicotine: the modifying influence of the dopamine D4 receptor gene. Health Psychol 1998; 17: 56-62.
41. Mutschler J, Abbruzzese E, von der Goltz C, Dinter C, Mobascher A, Thiele H, Diaz-Lacava A, Dahmen N, Gallinat J, Majic T, Petrovsky N, Kornhuber J, Thuerauf N, Gründer G, Brinkmeyer J, Wienker T, Wagner M, Winterer G, Kiefer F: Genetic variation in the neuropeptide Y gene promoter is associated with increased risk of tobacco smoking. Eur Addict Res 2012; 18: 246-252.
42. David SP, Strong DR, Munafò MR, Brown RA, Lloyd-Richardson EE, Wileyto PE, Evins EA, Shields PG, Lerman C, Niaura R: Bupropion efficacy for smoking cessation is influenced by the DRD2 Taq1A polymorphism: analysis of pooled data from two clinical trials. Nicotine Tob Res 2007; 9: 1251-1257.